Case Report: Immunotherapy for low-grade myofibroblastic sarcoma of the pharynx
Low-grade myofibroblastic sarcoma (LGMS) characterized by the increased proliferation of myofibroblasts is a rare type of malignant myofibroblastic tumor that frequently occurs in the head and neck region. Presently, there is no consensus regarding the treatment of LGMS. Here, we report a rare case...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-07-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1190210/full |
| _version_ | 1797788196551000064 |
|---|---|
| author | Bao Sun Bao Sun Zhiying Luo Zhiying Luo Ping Liu Yan He Shasha He Wenhui Liu Wenhui Liu |
| author_facet | Bao Sun Bao Sun Zhiying Luo Zhiying Luo Ping Liu Yan He Shasha He Wenhui Liu Wenhui Liu |
| author_sort | Bao Sun |
| collection | DOAJ |
| description | Low-grade myofibroblastic sarcoma (LGMS) characterized by the increased proliferation of myofibroblasts is a rare type of malignant myofibroblastic tumor that frequently occurs in the head and neck region. Presently, there is no consensus regarding the treatment of LGMS. Here, we report a rare case of LGMS of the pharynx in a 40-year-old male admitted to our hospital. The patient underwent resection for a right metastatic lesion and parapharyngeal mass. However, he had recurrence and multiple metastases without a surgical indication. Then the patient received the treatment of anlotinib plus pembrolizumab for 4 cycles, and there was a partial response (PR) to the treatment. Due to the adverse reaction of anlotinib, the patient subsequently received monotherapy of pembrolizumab for 22 cycles and achieved a complete response (CR). As the first case report of the immunotherapy for LGMS, our study highlights that this strategy may be of great significance to the treatment of LGMS. |
| first_indexed | 2024-03-13T01:32:11Z |
| format | Article |
| id | doaj.art-90405dc1fd7d473c9e8354df0396b62c |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-03-13T01:32:11Z |
| publishDate | 2023-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-90405dc1fd7d473c9e8354df0396b62c2023-07-04T06:47:22ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-07-011410.3389/fimmu.2023.11902101190210Case Report: Immunotherapy for low-grade myofibroblastic sarcoma of the pharynxBao Sun0Bao Sun1Zhiying Luo2Zhiying Luo3Ping Liu4Yan He5Shasha He6Wenhui Liu7Wenhui Liu8Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, ChinaInstitute of Clinical Pharmacy, Central South University, Changsha, ChinaDepartment of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, ChinaInstitute of Clinical Pharmacy, Central South University, Changsha, ChinaDepartment of Oncology, The Second Xiangya Hospital, Central South University, Changsha, ChinaDepartment of Oncology, The Second Xiangya Hospital, Central South University, Changsha, ChinaDepartment of Oncology, The Second Xiangya Hospital, Central South University, Changsha, ChinaDepartment of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, ChinaInstitute of Clinical Pharmacy, Central South University, Changsha, ChinaLow-grade myofibroblastic sarcoma (LGMS) characterized by the increased proliferation of myofibroblasts is a rare type of malignant myofibroblastic tumor that frequently occurs in the head and neck region. Presently, there is no consensus regarding the treatment of LGMS. Here, we report a rare case of LGMS of the pharynx in a 40-year-old male admitted to our hospital. The patient underwent resection for a right metastatic lesion and parapharyngeal mass. However, he had recurrence and multiple metastases without a surgical indication. Then the patient received the treatment of anlotinib plus pembrolizumab for 4 cycles, and there was a partial response (PR) to the treatment. Due to the adverse reaction of anlotinib, the patient subsequently received monotherapy of pembrolizumab for 22 cycles and achieved a complete response (CR). As the first case report of the immunotherapy for LGMS, our study highlights that this strategy may be of great significance to the treatment of LGMS.https://www.frontiersin.org/articles/10.3389/fimmu.2023.1190210/fulllow-grade myofibroblastic sarcomapharynxrecurrence and multiple metastasespembrolizumabimmunotherapy |
| spellingShingle | Bao Sun Bao Sun Zhiying Luo Zhiying Luo Ping Liu Yan He Shasha He Wenhui Liu Wenhui Liu Case Report: Immunotherapy for low-grade myofibroblastic sarcoma of the pharynx Frontiers in Immunology low-grade myofibroblastic sarcoma pharynx recurrence and multiple metastases pembrolizumab immunotherapy |
| title | Case Report: Immunotherapy for low-grade myofibroblastic sarcoma of the pharynx |
| title_full | Case Report: Immunotherapy for low-grade myofibroblastic sarcoma of the pharynx |
| title_fullStr | Case Report: Immunotherapy for low-grade myofibroblastic sarcoma of the pharynx |
| title_full_unstemmed | Case Report: Immunotherapy for low-grade myofibroblastic sarcoma of the pharynx |
| title_short | Case Report: Immunotherapy for low-grade myofibroblastic sarcoma of the pharynx |
| title_sort | case report immunotherapy for low grade myofibroblastic sarcoma of the pharynx |
| topic | low-grade myofibroblastic sarcoma pharynx recurrence and multiple metastases pembrolizumab immunotherapy |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1190210/full |
| work_keys_str_mv | AT baosun casereportimmunotherapyforlowgrademyofibroblasticsarcomaofthepharynx AT baosun casereportimmunotherapyforlowgrademyofibroblasticsarcomaofthepharynx AT zhiyingluo casereportimmunotherapyforlowgrademyofibroblasticsarcomaofthepharynx AT zhiyingluo casereportimmunotherapyforlowgrademyofibroblasticsarcomaofthepharynx AT pingliu casereportimmunotherapyforlowgrademyofibroblasticsarcomaofthepharynx AT yanhe casereportimmunotherapyforlowgrademyofibroblasticsarcomaofthepharynx AT shashahe casereportimmunotherapyforlowgrademyofibroblasticsarcomaofthepharynx AT wenhuiliu casereportimmunotherapyforlowgrademyofibroblasticsarcomaofthepharynx AT wenhuiliu casereportimmunotherapyforlowgrademyofibroblasticsarcomaofthepharynx |